Proton therapy for uveal melanomas and other eye lesions.
Charged particle beams are ideal for treating intra-ocular lesions, since they can be made to deposit their dose in the target, while significantly limiting dose received by non-involved ocular and orbital structures. Proton beam treatment of large numbers of uveal melanoma patients consistently achieves local control rates in excess of 95%, and eye retention rates of approximately 90%. Visual preservation is related to initial visual acuity, tumor size and location, and dose received by the macula, disc, and lens. The probability of distant metastasis is increased by larger tumor diameter, more anterior tumor location, and older patient age. Proton therapy is also effective treatment for patients with ocular angiomas, hemangiomas, metastatic tumors, and retinoblastomas, and may be beneficial for patients with exudative ("wet") age-related macular degeneration.
Department of Radiation Oncology, Massachusetts General Hospital, Harvard University Medical School, Boston, USA.
J E
JE
Munzenrider
D005134:Eye Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D005260:Female; D006391:Hemangioma / Q000532:radiotherapy; D006801:Humans; D008268:Macular Degeneration; D008297:Male; D008545:Melanoma / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D009362:Neoplasm Metastasis; D061766:Proton Therapy; D011879:Radiotherapy Dosage; D011881:Radiotherapy, Computer-Assisted; D012189:Retrospective Studies; D016019:Survival Analysis; D014604:Uveal Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D014792:Visual Acuity; D011522:Protons
D011522:Protons